Brentuximab after stem cell transplant for mycosis fungoides
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether giving a drug called brentuximab vedotin after a stem cell transplant can help keep your lymphoma in check and prevent it from coming back. It is for people with a specific type of lymphoma (mycosis fungoides) that has been hard to treat and who have recently had a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a type of lymphoma called mycosis fungoides that is at a later stage (IIB, III, IVA, or IVB) and shows a certain marker called CD30.
- You have had a recent stem cell transplant (from a sibling or a 9/10 or 10/10 matched or half-matched donor) that happened 60 to 90 days ago.
- Your lymphoma is currently in remission or at least partially responding after the transplant.
- Your liver, kidney, and blood counts are within acceptable levels, and you are generally well enough (performance status 0-1).
- You have tried at least one prior systemic treatment that did not work or your disease came back.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with a type of lymphoma called EBV-positive DLBCL that has not been treated before. The goal is to see if adding brentuximab vedotin to the standard R-CHP chemotherapy can improve outcomes.
This trial tests a new investigational drug (DT-7012) for people with a type of skin lymphoma that hasn't responded to standard treatments. The drug is given as an infusion and aims to boost your immune system to fight the cancer.
This trial tests the drug brentuximab vedotin for children and young adults (ages 2 to under 35) who have just been diagnosed with classical Hodgkin lymphoma. The treatment is guided by PET/CT scans to see how well it works.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This trial tests a combination of two drugs for people with a type of skin lymphoma that has not improved with earlier treatment. The goal is to see if the combination is safe and effective.
This Phase 2 study tests how brentuximab vedotin should be dosed for people with mycosis fungoides or Sezary syndrome (skin T-cell lymphoma), and also for lymphomatoid papulosis. It may help improve how well the treatment works while tracking side effects.
Hear when a new Brentuximab Vedotin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.